Antibody therapies called bispecific T cell engagers (BTEs) have emerged as effective treatments for some blood cancers but have been more difficult to develop for solid tumors. While clinically successful, first-generation BTEs suffer a short half-life. Now, Wistar scientists have built upon bispecific T cell engagers (BTEs) technology to develop…

Using large proteogenomic datasets, novel renal cell carcinoma (RCC) biomarkers were found in a new study led by University of Michigan Health Rogel Cancer Center researchers. The team carried out integrative analysis of datasets from both non-clear cell and clear cell RCC. Their findings should improve researchers’ ability to diagnose subtypes…

A drug regimen that combines VEGFR inhibitor drugs with a peptide, angiotensin-(1,7), which is generated by the ACE2 enzyme, can overcome treatment resistance and improve survival in mice with the common kidney cancer renal cell carcinoma (RCC), according to a team of researchers from the U.S. and Ireland. The team’s…

A new study in Cancer Cell reveals evolutionary clues in the tumor microenvironment during gastric cancer progression. Researchers from the University of Texas MD Anderson Cancer Center learned that the presence of certain types of cell groupings were linked with clinical outcomes. The study provides a high-resolution gastric cancer tumor…

A new renal cell carcinoma (RCC) model developed by researchers at The University of Texas MD Anderson Cancer Center has uncovered a cluster of interferon receptor (INFR) genes that trigger chromosomal instability and drive metastasis. The findings, published today in Nature Cancer may be a new tool for clinicians to…

An “off-the-shelf” allogeneic CAR T-cell therapy, developed by Allogene Therapeutics and tested by the University of Texas MD Anderson Cancer Center, showed promising results in a Phase I trial to treat patients with metastatic clear cell renal cell carcinoma. The advent of immunotherapy revolutionized cancer treatment. Combined gene and cell…

Immunotherapy is a common treatment for clear cell renal cell carcinoma (ccRCC), yet there are no tools to discern whether the treatment will be effective in individual patients. Now, researchers at the Francis Crick Institute, the Royal Marsden NHS Foundation Trust, and University College London (UCL) have published findings in…

Renal cell carcinomas (RCCs) are heterogeneous cancers encompassing several histologically and molecularly diverse tumor groups. Thought to arise from kidney tubular epithelial cells, clear cell RCC (ccRCC) is the most common type. A new study using single cell RNA sequencing (scRNA-seq) revealed the cellular origins for more than 10 RCC…

Many patients with clear cell renal carcinoma—the most common type of kidney cancer—eventually experience cancer recurrence and develop incurable metastatic disease. Now, a new study by researchers at Columbia University Vagelos College of Physicians and Surgeons shows promise in predicting which patients are likely to have their cancer recur after…

Researchers from the Johns Hopkins University School of Medicine have identified that gene expression profiling may assist in determining renal cell carcinoma patients who are unlikely to benefit from the anti-PD-L1 checkpoint inhibitor immunotherapy drug nivolumab (Opdivo). The recent study—“The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated…

Research teams from 39 institutions around the world collected and analyzed 91 samples of adrenocortical carcinoma (ACC)—hoping to improve our understanding about one of the rarest, and lethal, types of cancer. This comprehensive analysis was performed as part of The Cancer Genome Atlas (TCGA) Research Network. The investigators from this…

A machine learning pipeline that combines multiple omics datasets was used to derive a new transcriptomic footprint correlated with positive outcomes in patients with advanced kidney cancer who underwent immunotherapy. The approach identified the molecular characteristics of an immune signaling hub distinguished by a human leukocyte antigen (HLA) repertoire with…

Easily accessible information from hematoxylin and eosin (H&E)-stained tumor tissue on microscopy slides can predict which patients with metastatic clear cell renal cell carcinoma (mccRCC) are most likely to respond to immunotherapy, with the prediction further refined by adding PBRM1 mutation status, research suggests. The findings, from a retrospective study…

Results of a large-scale, international study of renal cell carcinoma (RCC) has shown that measuring mutations in 12 disease-related genes can stratify patients according to their risk for recurrence. The researchers, led by teams at the Leeds Institute of Medical Research at St. James’s in the U.K. and McGill University…

Sixteen splice variants were identified as potential biomarkers for clear cell renal cell carcinoma in a new study published in European Urology and led by researchers at Moffitt Cancer Center. The team also described a tool to indicate which patients are at high risk of poor outcomes based on their biomarker expression. “These…